A  first-in-class, repurposed small molecule combination therapy for the treatment of Opioid Use Disorder (OUD) designed to address the profound unmet needs of the current OUD crisis. This candidate offers a differentiated approach to current standards of care by targeting novel neurobiological pathways, moving beyond simple opioid receptor agonism/antagonism. The program is advancing to a pivotal Phase 2 clinical trial, supported by a robust preclinical package and a successful Phase 1 study